Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Net Resources International

23:56 EDT 18th September 2018 | BioPortfolio

Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.

More Information about Net Resources International on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.

Showing News Articles 1–25 of 556 from Net Resources International

Tuesday 18th September 2018

Will the UK relax its current regulations for cannabis-based products?

Recently medicinal cannabis has been at the forefront of media attention in the UK, and in July 2018 the UK...Read More... The post Will the UK relax its current regulations for cannabis-based products? appeared first on Drug Development Technology.

Monday 17th September 2018

Actelion reports positive results from Portico trial for PoPH

Actelion Pharmaceuticals has reported positive outcomes from the Portico trial after meeting the primary endpoint of the study. Portico is...Read More... The post Actelion reports positive results from Portico trial for PoPH appeared first on Drug Development Technology.

FDA lifts partial clinical hold on Mersana’s Phase l study of XMT-1522

The US Food and Drug Administration (FDA) has lifted the partial clinical hold on a Phase l study initiated by...Read More... The post FDA lifts partial clinical hold on Mersana’s Phase l study of XMT-1522 appeared first on Drug Development Technology.

GamaMabs Pharma doses first patient in Phase ll trial of GM102

GamaMabs Pharma has dosed the first patient in its Phase ll clinical trial of GM102 and in combination with Trifluridine/Tipiracil...Read More... The post GamaMabs Pharma doses first patient in Phase ll trial of GM102 appeared first on Drug Development Technology.

Sunday 16th September 2018

Millendo Therapeutics starts Phase llb trial of nevanimibe for CAH

Millendo Therapeutics has begun a Phase llb clinical trial to investigate the efficacy and safety of nevanimibe for the treatment...Read More... The post Millendo Therapeutics starts Phase llb trial of nevanimibe for CAH appeared first on Drug Development Technology.

MorphoSys and Galapagos start Phase l study of MOR106

MorphoSys and Galapagos have commenced a Phase l trial to evaluate MOR106 for the treatment of moderate-to-severe atopic dermatitis. The...Read More... The post MorphoSys and Galapagos start Phase l study of MOR106 appeared first on Drug Development Technology.

Pfizer reports positive data from Phase lla study for alopecia areata

Pfizer has reported positive data from a Phase lla trial that evaluated the efficacy, safety, and tolerability of PF-06651600 and...Read More... The post Pfizer reports positive data from Phase lla study for alopecia areata appeared first on Drug Development Technology.

Thursday 13th September 2018

Deals this week: Zealand Pharma, Fulcrum Therapeutics, Forendo Pharma

Zealand Pharma has sold its future royalty streams and potential commercial milestones for Soliqua® 100/33/Suliqua® and Lyxumia®/Adlyxin® to Royalty Pharma...Read More... The post Deals this week: Zealand Pharma, Fulcrum Therapeutics, Forendo Pharma appeared first on Drug Development Technology.

Boston Biomedical doses first patient in Phase l trial of DSP-0509

Boston Biomedical has dosed the first patient in a Phase l clinical trial to test the safety and pharmacokinetic of...Read More... The post Boston Biomedical doses first patient in Phase l trial of DSP-0509 appeared first on Drug Development Technology.

Janssen reports positive long-term results from Voyage 1 and 2 trials

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported positive long-term results from Phase lll Voyage 1 and 2...Read More... The post Janssen reports positive long-term results from Voyage 1 and 2 trials appeared first on Drug Development Technology.

M&As this week: Telix Pharmaceuticals, PCI Pharma, DZS Clinical Services

Telix Pharmaceuticals Limited has acquired Atlab Pharma SAS for $10m. Based in Australia, Telix is a clinical-stage biotechnology company engaged...Read More... The post M&As this week: Telix Pharmaceuticals, PCI Pharma, DZS Clinical Services appeared first on Drug Development Technology.

Wednesday 12th September 2018

Merck reports positive results from ASPECT-NP study for pneumonia

Merck has reported positive results from the ASPECT-NP study, after meeting the trial’s primary objectives of all-cause mortality at day...Read More... The post Merck reports positive results from ASPECT-NP study for pneumonia appeared first on Drug Development Technology.

Spectrum expands Phase ll trial of poziotinib for NSCLC

Spectrum Pharmaceuticals has expanded its Phase ll clinical trial of poziotinib for non-small cell lung cancer (NSCLC) by adding two...Read More... The post Spectrum expands Phase ll trial of poziotinib for NSCLC appeared first on Drug Development Technology.

Innovent doses first patient in Phase III sintilimab trial for NSCLC

China-based biopharmaceutical company Innovent Biologics has dosed the first patient in the Phase III ORIENT-11 trial designed to evaluate sintilimab...Read More... The post Innovent doses first patient in Phase III sintilimab trial for NSCLC appeared first on Drug Development Technology.

DesignMedix starts enrolment in Phase l trial of DM1157 for malaria

DesignMedix has started patient enrolment in a Phase l clinical trial to evaluate the safety of its investigational drug DM1157...Read More... The post DesignMedix starts enrolment in Phase l trial of DM1157 for malaria appeared first on Drug Development Technology.

Tuesday 11th September 2018

Lilly begins IXORA-R head-to-head trial for plaque psoriasis

Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of...Read More... The post Lilly begins IXORA-R head-to-head trial for plaque psoriasis appeared first on Drug Development Technology.

Imugene completes enrolment in Phase lb trial of IMU-131

Imugene has concluded patient enrolment in a Phase lb clinical trial of its HER-Vaxx cancer vaccine IMU-131 for the treatment...Read More... The post Imugene completes enrolment in Phase lb trial of IMU-131 appeared first on Drug Development Technology.

The UK is home to the world leader in plant-derived cannabinoid therapeutics

The UK is the leading exporter of legal cannabis for medical usage, responsible for 67.7% of the global production of...Read More... The post The UK is home to the world leader in plant-derived cannabinoid therapeutics appeared first on Drug Development Technology.

CAR-T toxicity rating system to be finalized by ASBMT by year-end

The American Society of Blood and Marrow Transplantation (ASBMT) is in the process of developing a toxicity rating system for...Read More... The post CAR-T toxicity rating system to be finalized by ASBMT by year-end appeared first on Drug Development Technology.

Cyclacel starts Phase lb/ll trial BRCA mutant breast cancer

Cyclacel Pharmaceuticals has commenced a Phase lb/ll clinical trial to investigate the safety and effectiveness of sapacitabine in combination with...Read More... The post Cyclacel starts Phase lb/ll trial BRCA mutant breast cancer appeared first on Drug Development Technology.

Monday 10th September 2018

Xspray Pharma reports positive results from HyNap-Dasa Phase I study

Xspray Pharma has reported positive data from a Phase I study of HyNap-Dasa in comparison with Sprycel for the treatment...Read More... The post Xspray Pharma reports positive results from HyNap-Dasa Phase I study appeared first on Drug Development Technology.

Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours

Alkermes has expanded its ongoing phase l clinical trial to examine the safety and anti-tumour activity of ALKS 4230 in...Read More... The post Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours appeared first on Drug Development Technology.

Why are novel therapies for glioblastoma patients not gaining approvals?

Despite the abundance of approvals and launches of novel therapies in the oncology space, glioblastoma multiforme (GBM), a solid tumor...Read More... The post Why are novel therapies for glioblastoma patients not gaining approvals? appeared first on Drug Development Technology.

Sunday 9th September 2018

ContraFect ends enrolment in Phase ll trial of CF-301

ContraFect has completed enrolment in the Phase ll clinical trial examining CF-301 (exebacase) as a potential treatment for Staphylococcus aureus...Read More... The post ContraFect ends enrolment in Phase ll trial of CF-301 appeared first on Drug Development Technology.

Compugen doses first patient in Phase l trial of COM701

Compugen has dosed the first patient in a Phase l clinical trial of COM701 for the treatment of patients with...Read More... The post Compugen doses first patient in Phase l trial of COM701 appeared first on Drug Development Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks